Progress of immunotherapy strategies for uveal melanoma
10.3760/cma.j.cn115355-20230131-00053
- VernacularTitle:葡萄膜黑色素瘤免疫治疗策略研究进展
- Author:
Xinpei JI
1
;
Mingyan HUANG
;
Qiuyan LIU
Author Information
1. 同济大学附属东方医院眼视光中心，上海 200120
- Keywords:
Melanoma;
Immune checkpoint inhibitors;
Immunotherapy;
Molecular targeted therapy;
Antineoplastic combined chemotherapy protocols
- From:
Cancer Research and Clinic
2023;35(8):629-633
- CountryChina
- Language:Chinese
-
Abstract:
Uveal melanoma (UM) is the most common intraocular malignancy in adults. Recently, great progresses have been made in the diagnosis, treatment and prognosis of UM, however, nearly 50% of patients still develop liver metastases, which severely affects on the survival of UM patients. Whether UM patients will benefit from the immune checkpoint blockade similarly as the cutaneous melanoma (CM)? Whether the specific gene mutations targeting UM could improve the anti-tumor efficacy? Whether chimeric antigen receptor T cell or T cell receptor T cell immunotherapy is effective to UM patients with liver metastases? How about the combinational therapies in UM and the clinical effects? This review summarizes the anti-tumor research and novel treatment options of UM, analyzes the current achievements and problems.
